Determination of naltrexone and 6-β-naltrexol in plasma by solid-phase extraction and gas chromatography-negative ion chemical ionization-mass spectrometry

Journal of Analytical Toxicology

Volumn 21, Issue 4, 1997, Pages 252-257

  Huang, Wei ^a   Moody, David E ^a,c   Foltz, Rodger L ^a   Walsh, Sharon L ^b  

^a UNIVERSITY OF UTAH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Biomedical Polymers Research Bldg   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NALTREXOL; NALTREXONE;

ADULT; ARTICLE; DRUG ABUSE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ISOLATION; GAS CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MASS SPECTROMETRY; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; QUANTITATIVE ASSAY; SOLID PHASE EXTRACTION;

EID: 0030749602     PISSN: 01464760     EISSN: None     Source Type: Journal    
DOI: 10.1093/jat/21.4.252     Document Type: Article

References (22)

1. T.A. Kosten and T.R. Kosten. Pharmacological blocking agents for treating substance abuse. J. Nerv. Ment. Dis. 179: 583-92 (1991).
2. J.R. Volpicella, A.I. Alterman, M. Hayashida, and C.P. O'Brien. Naltrexone in the treatment of alcohol dependence. Arch. Gen. Psychiatry 49: 876-80 (1992).
3. M. Campbell, J.E. Overall, A.M. Small, M.S. Sokol, E.K. Spencer, P. Adams, R.L. Foltz, K.M. Monti, R. Perry, M. Nobler, and E. Roberts. Naltrexone in autistic children: an acute open dose range tolerance trial. J. Am. Child Adolesc. Psychiatr. 28: 200-206 (1989).
4. N. Chatterjie, J.M. Fujimoto, C.E. Inturrisi, S. Roerig, I.H. Wang, D.V. Bowen, F.H. Field, and D.D. Clarke. Isolation and streochemical identification of a metabolite of naltrexone from human urine. Drug Metab. Dispos. 2: 401-405 (1974).
5. E.J. Cone, C.W. Gorodetzky, and S.Y. Yeh. The urinary excretion profile of naltrexone and metabolites in man. Drug Metab. Dispos. 2: 506-12 (1974).
6. E.J. Cone, C.W. Gorodetzky, and W.D. Darwin. The identification and measurement of two new metabolites of naltrexone in human urine. Res. Commun. Chem. Pathol. Pharmacol. 20: 413-33 (1978).
7. K. Verebey, A. De Pace, D. Jukofsky, J.V. Volvavka, and S.J. Mulé. Quantitative determination of 2-hydroxy-3-methoxy-6β-naltrexol (HMN), naltrexone, and 6β-naltrexol in human plasma, red blood cells, saliva, and urine by gas liquid chromatography. J. Anal. Toxicol. 4: 33-37 (1980).
8. K. Verebey, J. Volavka, S.J. Mulé, and R.B. Resnick. Naltrexone: disposition, metabolism, and effects after acute and chronic dosing. Clin. Pharmacol. Ther. 20: 315-28 (1976).
9. M.E. Wall, D.R. Brine, and M. Perez-Reyes. Metabolism and disposition of naltrexone in man after oral and intravenous administration. Drug Metab. Dispos. 9: 370-75 (1981).
10. M.E. Wall, M. Perez-Reyes, D.R. Brine, and C.E. Cook. Naltrexone disposition in man after subcutaneous administration. Drug Metab. Dispos. 12: 677-82 (1984).
11. C.N. Chiang, L.E. Hollister, A. Kishimoto, and G. Barnett. Kinetics of naltrexone sustained-release preparation. Clin. Pharmacol. Ther. 36: 704-708 (1984).
12. K. Verebey, J. Alarazi, M. Lehrer, and S.J. Mulé. Determination of 6-β-naltrexol and naltrexone by bonded-phase adsorption thin-layer chromatography. J. Chromatogr. 378: 261-66 (1986).
13. E.F. O'Connor, S.W.T. Cheng, and W.G. North. Simultaneous extraction and chromatographic analysis of morphine, dilaudid, naltrexone and naloxone in biological fluids by high-performance liquid chromatography with electrochemical detection. J. Chromatogr. 491: 240-47 (1989).
14. P. Zuccaro, I. Altieri, P. Betto, R. Pacifici, G. Ricciarello, L.A. Pini, E. Sternieri, and S. Pichini. Determination of naltrexone and 6-β-naltrexol in plasma by high-performance liquid chromatography with coulometric detection. J. Chromatogr. 567: 485-90 (1991).
15. G.L. Burce, N.B. Bhat, and T. Sokoloski. Quantitative determination of naltrexone and naltrexone prodrugs by electron-capture gas-liquid chromatography. J. Chromatogr. 137: 323-32 (1977).
16. K.M. Monti, R.L. Foltz, and D.M. Chinn. Analysis of naltrexone and 6-β-naltrexol in plasma and urine by gas chromatography/negative ion chemical ionization mass spectrometry. J. Anal. Toxicol. 15: 136-40 (1991).
17. C.C. Nelson, M.D. Fraser, J.K. Wilfahrt, and R.L. Foltz. Gas chromatography tandem mass spectrometry measurement of delta(9)-tetrahydrocannabinol, naltrexone, and their active metabolites in plasma. Ther. Drug Monit. 15: 557-62 (1993).
18. S.L. Walsh, K.L. Preston, G.E. Bigelow, and M.L. Stitzer. Acute administration of buprenorphine in humans: partial agonist and blockade effects. J. Pharmacol. Exp. Ther. 274: 361-72 (1995).
19. K.J. Schuh, S.L. Walsh, and M.L. Stitzer. A comparison of buprenorphine's and naltrexone's opioid blockade abilities. NIDA Res. Monogr. 153: 254 (1995).
20. P. Lillsunde and T. Korte. Comprehensive drug screening in urine using solid-phase extraction and combined TLC and GC/MS identification. J. Anal. Toxicol. 15: 71-81 (1991).
21. R. Pocci, V. Dixit, and V.M. Dixit. Solid-phase extraction and GC/MS confirmation of barbiturates from human urine. J. Anal. Toxicol. 16: 45-47 (1992).
22. R.H. Sample and J.C. Baenziger. Gas chromatography/mass spectrometry screening for anabolic steroids. In Analytical Aspects of Drug Testing. D.G. Deutsch, Ed. John Wiley & Sons, Inc., New York, NY, 1989. pp 259-61.